人体单核细胞中1,25(OH)₂维生素D₃受体在体内上调的证据。
Evidence for in vivo upregulation of 1,25(OH)2 vitamin D3 receptor in human monocytes.
作者信息
Merke J, Nawrot M, Hügel U, Szabo A, Ritz E
机构信息
Department of Internal Medicine, University of Heidelberg, Federal Republic of Germany.
出版信息
Calcif Tissue Int. 1989 Oct;45(4):255-6. doi: 10.1007/BF02556046.
Mammalian cells increase net expression of 1,25(OH) 2D3 receptors after exposure to physiological concentrations of 1,25(OH) 2D3 in vitro. We examined specific binding of 1,25(OH) 2D3 by human monocytes before and after daily administration of 1.5-2 micrograms 1,25(OH) 2D3 p.o. for 3 days in 5 healthy normal D-replete probands. Median specific binding (Nmax) at baseline was 793 molecules/cell and 2052 or 2828 at 24h and 72h of 1,25(OH) 2D3 treatment respectively. The results suggest (a) upregulation of 1,25(OH) 2D3 receptors occurs in man and (b) monocyte preparations can be used to assess receptor regulation in vivo.
在体外暴露于生理浓度的1,25(OH)₂D₃后，哺乳动物细胞会增加1,25(OH)₂D₃受体的净表达。我们检测了5名健康、维生素D充足的正常受试者在口服每日1.5 - 2微克1,25(OH)₂D₃，持续3天前后，人单核细胞对1,25(OH)₂D₃的特异性结合情况。基线时特异性结合的中位数（Nmax）为793个分子/细胞，在1,25(OH)₂D₃治疗24小时和72小时时分别为2052个分子/细胞和2828个分子/细胞。结果表明：（a）在人体中会发生1,25(OH)₂D₃受体的上调；（b）单核细胞制剂可用于评估体内的受体调节情况。
Zotero 插件